Products mentioned by Alex Tatem
Products Alex Tatem has mentioned or recommended across podcast appearances.
SignalCast may earn a small commission on purchases through these links — at no extra cost to you. As an Amazon Associate we earn from qualifying purchases.
KPV
“In July 2025, seven peptides—BPC-157, TB-500, KPV, MOTS-c, D-SIP, Epithalon, and Semax—are scheduled for review to return to Category 1”
D-SIP
“In July 2025, seven peptides—BPC-157, TB-500, KPV, MOTS-c, D-SIP, Epithalon, and Semax—are scheduled for review to return to Category 1”
Tesamorelin
“Tesamorelin, a growth hormone releasing hormone derivative, is currently commercially available via prescription at CVS or Walgreens and specifically targets visceral abdominal fat at a disproportionate rate compared to other compounds.”
Manjaro
by Eli Lilly
“Branded Manjaro (tirzepatide) delivers one standardized weekly dose via auto-injector pen.”
Epithalon
“In July 2025, seven peptides—BPC-157, TB-500, KPV, MOTS-c, D-SIP, Epithalon, and Semax—are scheduled for review to return to Category 1”
BPC-157
“seven peptides—including BPC-157 and TB-500—are scheduled for re-legalization review in July 2025. BPC-157, for example, has no established LD-1 dose, meaning researchers cannot determine a quantity harmful to even 1% of test subjects, making it among the most well-tolerated compounds studied in animal models.”
Semax
“In July 2025, seven peptides—BPC-157, TB-500, KPV, MOTS-c, D-SIP, Epithalon, and Semax—are scheduled for review to return to Category 1”
Tirzepatide
“Compounded tirzepatide with niacinamide from a 503A pharmacy allows microdosing—splitting the weekly amount into multiple smaller injections—which reduces nausea and end-of-week hunger rebound”
Retrotide
by Eli Lilly
“Dr. Tatem revealed that Retrotide, Lilly's forthcoming triple-receptor GLP-1 drug targeting GLP-1, GIP, and glucagon simultaneously, has already been self-administered by bodybuilders and biohackers for two years via research-use-only markets”
MOTS-c
“In July 2025, seven peptides—BPC-157, TB-500, KPV, MOTS-c, D-SIP, Epithalon, and Semax—are scheduled for review to return to Category 1”
TB-500
“seven peptides—including BPC-157 and TB-500—are scheduled for re-legalization review in July 2025.”